City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation

Border Border
Click here to login to Secure Web Site   (authorized users only)  
Search results:  411  Clinical trial(s) found  (Page 1 of 17 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for :
COH Protocol Number: 18380

Principal Investigator: Jeannine Mccune, PharmD
Sponsor: Institutional

Title:  Pilot Study to Evaluate Substances in Sweat, Saliva, and Blood

COH Protocol Number: 18361

Principal Investigator: Brooke Crawford, MD
Sponsor: Institutional

Title:  Robot Assistance for CT Guided Needle Placement

COH Protocol Number: 18306

Principal Investigator: Victoria Seewaldt, MD
Sponsor: Institutional

Title:  Food Deserts and Insulin Resistance

COH Protocol Number: 18295

Principal Investigator: Veronica Jones, MD
Sponsor: Institutional

Title:  Predictors of Chemoresistance in Locally Advanced Luminal B Breast Cancer

COH Protocol Number: 18294

Principal Investigator: Arya Amini, MD
Sponsor: Institutional

Title:  Geriatric Assessment and Quality of Life in Older Adults Undergoing Chemoradiation for Head and Neck Cancer and Their Family Caregivers

COH Protocol Number: 18289 Number: NCT03504397

Principal Investigator: Joseph Chao, MD
Sponsor: Industrial

Title:  A Phase 3, Global, Multi-Center, Double- Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

COH Protocol Number: 18280 Number: NCT03600883

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 1, First-in-Human, Open-label Study Evaluating the Safety,Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation

COH Protocol Number: 18278

Principal Investigator: Marwan Fakih, MD
Sponsor: Institutional

Title:  Individual Patient Supply of BVD-523 for a Patient (WG) with Colorectal Cancer

COH Protocol Number: 18269 Number: NCT03327857

Principal Investigator: Haris Ali, MD
Sponsor: Industrial

Title:  A Phase I Study of Neihulizumab (AbGn-168H) in Patients with Steroid-refractory Acute Graft-versus-host Disease (sr-aGvHD)

COH Protocol Number: 18263 Number: NCT03541369

Principal Investigator: Anthony Stein, MD
Sponsor: Industrial

Title:  A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

COH Protocol Number: 18254 Number: NCT03671018

Principal Investigator: L. elizabeth Budde, MD, PhD
Sponsor: Industrial

Title:  An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluation the Safety, Tolerability, Pharmacokinetics and Efficacy of Mosunetuzumab (BTCT4465A) in Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma

COH Protocol Number: 18248 Number: NCT03560531

Principal Investigator: Joanne Mortimer, MD
Sponsor: Industrial

Title:  A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Zn-C5 Alone and in Combination with Palbociclib in Subjects with Previously Treated Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer

COH Protocol Number: 18243

Principal Investigator: Thomas Slavin, MD
Sponsor: Institutional

Title:  Mechanisms and Dynamics of Clonal Hematopoiesis of Indeterminate Potential

COH Protocol Number: 18231 Number: NCT03155997

Principal Investigator: Joanne Mortimer, MD
Sponsor: Industrial

Title:  A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

COH Protocol Number: 18228 Number: NCT02432235

Principal Investigator: Jasmine Zain, MD
Sponsor: Industrial

Title:  A Phase I Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

COH Protocol Number: 18227 Number: NCT03193190

Principal Investigator: Vincent Chung, MD
Sponsor: Industrial

Title:  A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

COH Protocol Number: 18220

Principal Investigator: Jeffrey Wong, MD
Sponsor: Industrial

Title:  Clinical Protocol of the ARad™ Biodosimetry System in the Human TBI Population

COH Protocol Number: 18219 Number: NCT02834013

Principal Investigator: Vincent Chung, MD
Sponsor: Cooperative Group

Title:  SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

COH Protocol Number: 18216 Number: NCT02730299

Principal Investigator: Nicole Karras, MD
Sponsor: Industrial

Title:  A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies

COH Protocol Number: 18213 Number: NCT02580448

Principal Investigator: James Waisman, MD
Sponsor: Industrial

Title:  A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVID) in Subjects with Advanced Breast Cancer

COH Protocol Number: 18210 Number: NCT03549338

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Phase 2, Randomized, Open-Label, Multicenter, Three-Arm Trial of Sym004 versus each of its Component Monoclonal Antibodies, Futuximab and Modotuximab, in Patients with Chemotherapy-Refractory Metastatic Colorectal Carcinoma and Acquired Resistance to Anti-EGFR Monoclonal Antibody Therapy

COH Protocol Number: 18208 Number: NCT03459040

Principal Investigator: Karamjeet Sandhu, MD
Sponsor: Institutional

Title:  A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption of Steroid-Refractory Acute GVHD

COH Protocol Number: 18206 Number: NCT03589326

Principal Investigator: Ibrahim Aldoss, MD
Sponsor: Industrial

Title:  A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

COH Protocol Number: 18201

Principal Investigator: Lisa Yee, MD
Sponsor: Institutional

Title:  Aromatase Inhibitors, Joint Arthropathy, and Estrogen-Androgen Hormonal Imbalance

COH Protocol Number: 18165

Principal Investigator: David Snyder, MD
Sponsor: Institutional

Title:  Individual Patient Supply of Oral Pacritinib for a Patient (RG) with Thrombocytopenia and Primary Myelofibrosis

Results per page: 25 50 100 All 1-25 Trials Jump to page:

NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.